ArticleRSC advances2019
Evaluation of anti-EGFR-iRGD recombinant protein with GOLD nanoparticles: synergistic effect on antitumor efficiency using optimized deep neural networks.
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 14 citations in OpenAlex.
- Battling COVID-19 leveraging nanobiotechnology: Gold and silver nanoparticle-B-escin conjugates as SARS-CoV-2 inhibitors.Open life sciences · 2025Article
- Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review.Frontiers in medicine · 2025Review
- Molecular Docking Approach for Biological Interaction of Green Synthesized Nanoparticles.Molecules (Basel, Switzerland) · 2024Review
- Article
- Nanotheranostic Applications for Detection and Targeting Neurodegenerative Diseases.Frontiers in neuroscience · 2020Review
- Globally ncRNAs Expression Profiling of TNBC and Screening of Functional lncRNA.Frontiers in bioengineering and biotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor, also known as EGFR, is a tyrosine kinase receptor commonly found in epithelial tumors. As part of the first target for cancer treatment, EGFR has been the subject of intense research for more than 20 years; as a result, there are a number of anti-EGFR agents currently available. More recently, with our basic understanding of mechanisms related to receptor activation and function, both the secondary and primary forms of EGFR somatic mutations have led to the discovery of new anti-EGFR agents aimed at providing new insights into the clinical targeting of this receptor and possibly acting as an ideal model for developing strategies to target other types of receptors. In this study, we use genomic pattern to prove that
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.